Cargando…
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Patients & methods: Outpatient adults/adolescents with mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to s...
Autores principales: | Horga, Arantxa, Saenz, Rebecca, Yilmaz, Gürdal, Simón-Campos, Abraham, Pietropaolo, Keith, Stubbings, William J, Collinson, Neil, Ishak, Laura, Zrinscak, Barbara, Belanger, Bruce, Granier, Catherine, Lin, Kai, C Hurt, Aeron, Zhou, Xiao-Jian, Wildum, Steffen, Hammond, Janet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621114/ https://www.ncbi.nlm.nih.gov/pubmed/37928891 http://dx.doi.org/10.2217/fvl-2023-0115 |
Ejemplares similares
-
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
por: Horga, Arantxa, et al.
Publicado: (2023) -
A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)
por: Boffito, Marta, et al.
Publicado: (2023) -
Don Giovanni KV 527
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1992) -
Investigating the transmission of baloxavir‐resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study
por: Harding, Joanne, et al.
Publicado: (2023) -
Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus
por: Good, Steven S., et al.
Publicado: (2020)